Filtered By:
Condition: Atrial Fibrillation
Drug: Insulin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 49 results found since Jan 2013.

U-shaped association between the triglyceride-glucose index and atrial fibrillation incidence in a general population without known cardiovascular disease
CONCLUSIONS: A U-shaped association between the TyG index and AF incidence is observed in Americans without known cardiovascular diseases. Female sex may be a modifier in the association between the TyG index and AF incidence.PMID:37208737 | DOI:10.1186/s12933-023-01777-9
Source: Atherosclerosis - May 19, 2023 Category: Cardiology Authors: Xiao Liu Ayiguli Abudukeremu Yuan Jiang Zhengyu Cao Maoxiong Wu Jianyong Ma Runlu Sun Wanbing He Zhiteng Chen Yangxin Chen Peng Yu Wengen Zhu Yuling Zhang Jingfeng Wang Source Type: research

Usefulness of Triglyceride-glucose index for detecting prevalent atrial fibrillation in a type 2 diabetic population
CONCLUSION: Our data supported a linear and robust correlation between TyG and the prevalent AF in a diabetic population. Moreover, our results implicated the potential usefulness of TyG to refine the detection of prevalent AF in a diabetic population.PMID:36093727 | DOI:10.1080/00325481.2022.2124088
Source: Postgraduate Medicine - September 12, 2022 Category: Internal Medicine Authors: Wenrui Shi Mu Qin Shaohui Wu Kai Xu Qidong Zheng Xu Liu Source Type: research

Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry
ConclusionsIn a real-world cohort of AF patients on edoxaban, diabetes requiring insulin therapy, rather than the presence of diabetes per se, appears to be an independent factor affecting the occurrence of thromboembolic events during follow-up. Regardless of the diabetes type, diabetic patients had a lower survival compared with those without diabetes.Graphical abstract
Source: Clinical Research in Cardiology - August 17, 2022 Category: Cardiology Source Type: research

IJERPH, Vol. 19, Pages 4807: Stroke Risk Factors of Stroke Patients in China: A Nationwide Community-Based Cross-Sectional Study
Conclusions: The most common risk factors for community stroke patients in China are hypertension, dyslipidemia, and overweight or obesity. The stroke community patients’ suboptimal awareness and treatment of hypertension, and suboptimal awareness, treatment, and control of diabetes, and dyslipidemia are significant problems in China.
Source: International Journal of Environmental Research and Public Health - April 15, 2022 Category: Environmental Health Authors: Jingyi Chen Qianrang Zhu Lianlong Yu Yuqian Li Shanshan Jia Jian Zhang Tags: Article Source Type: research

Hemichorea in ketotic hyperglycemia with hyperdense striatum mimicking hemorrhagic transformation in a patient using apixaban.
CONCLUSION: Diabetic striatopathy is a rare but treatable disorder and should be considered in patients with poorly controlled diabetes who present with hemichorea. PMID: 33307650 [PubMed - as supplied by publisher]
Source: Neuroendocrinology Letters - December 16, 2020 Category: Endocrinology Tags: Neuro Endocrinol Lett Source Type: research

Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation.
CONCLUSION: In patients with AF, DM increases the risk of ischemic stroke, regardless of treatment. PMID: 33130017 [PubMed - as supplied by publisher]
Source: Vascular Pharmacology - October 28, 2020 Category: Drugs & Pharmacology Authors: Jensen T, Olesen KKW, Caterina, Würtz M, Kristensen SD, Maeng M Tags: Vascul Pharmacol Source Type: research

Stroke in the patient with diabetes (part 1) – Epidemiology, etiology, therapy and prognosis
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. The increase in the frequency of stroke is due to an increase in cerebral infarction, mainly lacunar infarcts, with the incidence of cerebral hemorrhage being less frequent. The major risk factors for stroke in the type 2 diabetic patient are age, hypertension, the number of features of the Metabolic Syndrome, the presence of diabetic nephropathy in both the type 1 and type 2 patient, the presence of peripheral and coronary artery disease and especially the...
Source: Diabetes Research and Clinical Practice - May 18, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Stroke in the patient with diabetes (Part 1) - Epidemiology, etiology, therapy and prognosis
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. The increase in the frequency of stroke is due to an increase in cerebral infarction, mainly lacunar infarcts, with the incidence of cerebral hemorrhage being less frequent. The major risk factors for stroke in the type 2 diabetic patient are age, hypertension, the number of features of the Metabolic Syndrome, the presence of diabetic nephropathy in both the type 1 and type 2 patient, the presence of peripheral and coronary artery disease and especially the...
Source: Diabetes Research and Clinical Practice - May 18, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. Stroke primary prevention can be achieved by controlling atrial fibrillation and hypertension, and the utilization of statins and anticoagulant therapies. Utilizing pioglitazone and GLP-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, DPP-4 and SGLT-2 inhibitors have no effect.
Source: Diabetes Research and Clinical Practice - May 11, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Stroke in the patient with diabetes (Part 2) -Prevention and the effects of glucose lowering therapies
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. Stroke primary prevention can be achieved by controlling atrial fibrillation and hypertension, and the utilization of statins and anticoagulant therapies. Utilizing pioglitazone and GLP-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, DPP-4 and SGLT-2 inhibitors have no effect.
Source: Diabetes Research and Clinical Practice - May 11, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Medical Management for Secondary Stroke Prevention
This article reviews the evidence base and recommendations for medical management for secondary stroke prevention. RECENT FINDINGS Recent developments for secondary stroke prevention include evidence to support the use of short-term dual antiplatelet therapy after minor stroke and transient ischemic attack, direct oral anticoagulants for nonvalvular atrial fibrillation, reversal agents for direct oral anticoagulant–associated hemorrhage, and aspirin rather than presumptive anticoagulation with a direct oral anticoagulant for embolic stroke of undetermined source. SUMMARY Most strokes are preventable. The mainstays ...
Source: CONTINUUM: Lifelong Learning in Neurology - April 1, 2020 Category: Neurology Tags: REVIEW ARTICLES Source Type: research

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news